News

The best and worst airlines stocks of 2024

It has been feast or famine for the airline industry this year. An uneven merger landscape had a ripple effect on several players, and a sector-wide shift towards the premium end of the market left budget carriers scrambling to rethink their business models. That chaos showed up in stock prices, which ranged from nearly triple-digit losses to triple-digit gains.

FDA says knockoff versions of Lilly obesity drug must come off the market

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday. The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. The decision is a win for Lilly — which had been pressing the FDA to take the step for months — and is expected to impact how patients access the drugs, including how much they pay.

Office Rebound Expected in 2025 While Other Real Estate Stocks to See Trouble

(Bloomberg) -- It’s been a challenging couple of years for real estate stocks since the Federal Reserve started raising interest rates in 2022, as borrowing costs soared and the property market collapsed. And despite a healthy rebound in the middle of 2024, the outlook for 2025 isn’t particularly encouraging.Most Read from BloombergNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets a